Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP.

Nat Rev Drug Discov. 2006 Sep;5(9):755-68. Review.

2.

NO-independent, haem-dependent soluble guanylate cyclase stimulators.

Stasch JP, Hobbs AJ.

Handb Exp Pharmacol. 2009;(191):277-308. doi: 10.1007/978-3-540-68964-5_13. Review.

PMID:
19089334
3.
4.

Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.

Boerrigter G, Burnett JC Jr.

Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. Review.

PMID:
17445086
5.

The chemistry and biology of soluble guanylate cyclase stimulators and activators.

Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, Schäfer M, Schirok H, Stasch JP, Stoll F, Straub A.

Angew Chem Int Ed Engl. 2013 Sep 2;52(36):9442-62. doi: 10.1002/anie.201302588. Epub 2013 Aug 20. Review.

PMID:
23963798
6.

Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.

Priviero FB, Webb RC.

J Cardiovasc Pharmacol. 2010 Sep;56(3):229-33. doi: 10.1097/FJC.0b013e3181eb4e75. Review.

7.

NO- and haem-independent soluble guanylate cyclase activators.

Schmidt HH, Schmidt PM, Stasch JP.

Handb Exp Pharmacol. 2009;(191):309-39. doi: 10.1007/978-3-540-68964-5_14. Review.

PMID:
19089335
8.

Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.

Doggrell SA.

Curr Opin Investig Drugs. 2005 Sep;6(9):874-8. Review.

PMID:
16187686
9.

New insights into the role of soluble guanylate cyclase in blood pressure regulation.

Buys E, Sips P.

Curr Opin Nephrol Hypertens. 2014 Mar;23(2):135-42. doi: 10.1097/01.mnh.0000441048.91041.3a. Review.

10.

Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.

Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP.

Int J Impot Res. 2002 Feb;14(1):8-14. Review.

11.

Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.

Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE.

Curr Drug Targets. 2012 Aug;13(9):1207-14. Review.

PMID:
22716077
12.

Guanylate cyclase activators, cell volume changes and IOP reduction.

Ellis DZ.

Cell Physiol Biochem. 2011;28(6):1145-54. doi: 10.1159/000335866. Epub 2011 Dec 16. Review.

13.

Soluble guanylate cyclase activation with cinaciguat: a new approach to the treatment of decompensated heart failure.

Hingorany S, Frishman WH.

Cardiol Rev. 2011 Jan-Feb;19(1):23-9. doi: 10.1097/CRD.0b013e3181fc1c10. Review.

PMID:
21135599
14.

Cardiovascular effects of modulators of soluble guanylyl cyclase activity.

Hoenicka M, Schmid C.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):287-301. Review.

PMID:
18855642
15.

Regulation of nitric oxide-sensitive guanylyl cyclase.

Friebe A, Koesling D.

Circ Res. 2003 Jul 25;93(2):96-105. Review.

16.
17.

Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.

Stasch JP, Schlossmann J, Hocher B.

Curr Opin Pharmacol. 2015 Apr;21:95-104. doi: 10.1016/j.coph.2014.12.014. Epub 2015 Jan 31. Review.

18.

Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J; Academic Research Team in Heart Failure (ART-HF).

Heart Fail Rev. 2013 Mar;18(2):123-34. doi: 10.1007/s10741-012-9323-1. Review.

PMID:
22622468
19.

Soluble guanylate cyclase modulators in heart failure.

Mitrovic V, Jovanovic A, Lehinant S.

Curr Heart Fail Rep. 2011 Mar;8(1):38-44. doi: 10.1007/s11897-010-0045-1. Review.

PMID:
21207207
20.

Modulation of cGMP in heart failure: a new therapeutic paradigm.

Boerrigter G, Lapp H, Burnett JC.

Handb Exp Pharmacol. 2009;(191):485-506. doi: 10.1007/978-3-540-68964-5_21. Review.

Items per page

Supplemental Content

Write to the Help Desk